The purpose of this trial is to determine that sort term calorie restriction will affect tumor biology in biopsy proven breast, endometrial or prostate cancers, which will positively impact biomarkers including miR-21, an onco-miR known to impact cancer outcomes.
PRIMARY OBJECTIVES: 1\) Investigate if caloric restriction will change serum micro ribonucleic acid (RNA) 21 (miR-21) expression in patients with prostate, endometrial or breast cancer. SECONDARY OBJECTIVES: 1. Investigate measurable changes induced by caloric restriction on both patient (host) and tumor characteristics from caloric restriction. 2. Investigate the adherence of the patient to the diet. 4\) Weight, height, and body composition will be assessed via BodyMetrix. BodyMetrix uses ultrasound technology to measure subcutaneous fat. 5\) Patients will have psycho-social evaluation using the Functional Assessment of Cancer Therapy-Prostate (FACT-P) test (prostate cancer), FACT-Breast (B) test (breast cancer), or the FACT-Endometrial Cancer (En) test (endometrial cancer) and the Patient Reported Outcomes Measurement Information System (PROMIS) cancer fatigue short form at baseline, midway through diet, and at the conclusion of the diet. 6\) Patient's nutritional status (Mini Nutritional Assessment \[MNA\] form) will be assessed, and their caloric needs will be calculated. 7\) Local recurrence, progression free survival, distant metastases and overall survival will be assessed.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
49
Undergo caloric restriction diet
Undergo counselor-led dietary counseling
Undergo standard of care surgery
Thomas Jefferson University
Philadelphia, Pennsylvania, United States
Change in miR-21 expression assessed in serum
Will be evaluated by a two-sided paired t-test at significance level 0.05.
Time frame: Baseline up to 12 weeks
Overall adherence with diet intervention defined as 90% of all logged events meeting the diet restriction target
Time frame: Up to 12 weeks
Change in body composition, assessed via BodyMetrix
Will be analyzed via a paired t-test.
Time frame: Baseline up to 12 weeks
Change in prostate tumor gene expression
Time frame: Baseline up to 12 weeks
Change in weight, defined as a percent change
Will be assessed by modeling BMI as a function of time via mixed-effects regression.
Time frame: Baseline up to 12 weeks
Change in temperature
Will be assessed as a function of time via mixed-effects regression.
Time frame: Baseline up to 12 weeks
Change in genomic expression of microRNA 21 (miR-21)
Initial cancer biopsy specimen for genomic analysis will be comped to definitive surgical specimens.
Time frame: Baseline to after definitive surgery
Change in insulin
Will be assessed as a function of time via mixed-effects regression.
Time frame: Baseline up to 12 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Change in biome analysis assessed by rectal swab
Time frame: Baseline to 12 weeks
Change in psycho-social outcomes, assessed by the FACT-B
Will be assessed as a function of time via mixed-effects regression.
Time frame: Baseline up to 12 weeks
Changes in nutritional status assessed by a Mini Nutritional Assessment (MNA)
Will be assessed as a function of time via mixed-effects regression.
Time frame: Baseline up to 12 weeks
Local recurrence, assessed through patient records
Will be analyzed via survival methods, specifically the Kaplan-Meier method and the log-rank test. If sufficient events occur, may assess the impact of various patient and clinical/treatment variables on these outcomes via Cox proportional hazards regression. Will be assessed and compared with historic controls using the Kaplan Meier method.
Time frame: From the date of study enrollment to time of event, assessed up to 12 weeks
Distant metastases, assessed through patient records
Will be analyzed via survival methods, specifically the Kaplan-Meier method and the log-rank test. If sufficient events occur, may assess the impact of various patient and clinical/treatment variables on these outcomes via Cox proportional hazards regression. Will be assessed and compared with historic controls using the Kaplan Meier method.
Time frame: From the date of study enrollment to time of event, assessed up to 12 weeks
Progression free survival, assessed through patient records
Will be analyzed via survival methods, specifically the Kaplan-Meier method and the log-rank test. If sufficient events occur, may assess the impact of various patient and clinical/treatment variables on these outcomes via Cox proportional hazards regression. Will be assessed and compared with historic controls using the Kaplan Meier method.
Time frame: From the date of study enrollment to time of event, assessed up to 12 weeks
Overall survival, assessed through patient records
Will be analyzed via survival methods, specifically the Kaplan-Meier method and the log-rank test. If sufficient events occur, may assess the impact of various patient and clinical/treatment variables on these outcomes via Cox proportional hazards regression. Will be assessed and compared with historic controls using the Kaplan Meier method.
Time frame: From the date of study enrollment to time of event, assessed up to 12 weeks
Change in weight, defined by body mass index as weight in kg divided by height in meters squared
Will be assessed by modeling BMI as a function of time via mixed-effects regression.
Time frame: Baseline up to 12 weeks
Change in blood pressure
Will be assessed as a function of time via mixed-effects regression.
Time frame: Baseline up to 12 weeks
Change in heart rate
Will be assessed as a function of time via mixed-effects regression.
Time frame: Baseline up to 12 weeks
Change in respiratory rate
Will be assessed as a function of time via mixed-effects regression.
Time frame: Baseline up to 12 weeks
Change in psycho-social outcomes, assessed by the FACT-P
Will be assessed as a function of time via mixed-effects regression.
Time frame: Baseline up to 12 weeks
Change in psycho-social outcomes, assessed by the FACT-En
Will be assessed as a function of time via mixed-effects regression.
Time frame: Baseline up to 12 weeks
Change in psycho-social outcomes, assessed by the POMIS cancer fatigue short form
Will be assessed as a function of time via mixed-effects regression.
Time frame: Baseline up to 12 weeks